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Abstract 
Introduction: The aim of the study was to determine the frequency of occurrence of antibodies participating in the development of en-
docrine diseases in patients with autoimmune haematopoietic disease, thus documenting the potential suitability of specific diagnostic 
and screening tests.
Material and methods: The study group consisted of 124 persons (men and women) with newly diagnosed pernicious anaemia (PA) 
and a control group (C) of 41 healthy people. Antibodies against: intrinsic factor (IFAb), gastric parietal cells (APCA), thyroid peroxidase 
(TPOAb), thyroglobulin (TgAb), adrenal cortex (AdrenalAb), and pituitary anterior lobe (PituitaryAb) were determined in the blood.
Results: 1. The risk of the presence of antibodies against endocrine glands in patients with PA can be classified in order: TPOAb and/or 
TgAb — 41.1%, TPOAb — 36.3%, TgAb — 25.0%, TPOAb and TgAb — 20.2%, AdrenalAb — 1.6%, PituitaryAb — 0.8%. 2. TPOAb and/or 
TgAb (mainly TPOAb) are more frequently present in patients with PA, who have IFAb and/or APCA. This correlation is most evident in 
patients with simultaneous occurrence of IFAb and APCA. 3. Among patients with PA, the simultaneous presence of antibodies IFAb and/
or APCA with TPOAb and/or TgAb antibodies is most likely in women over 45 years of age. 4. In group C, 12% had at least one of two 
antithyroid antibodies (TgAb twice as often as TPOAb), and 2.4% had both. AdrenalAb and PituitaryAb are not found in healthy persons.
Conclusions: In patients with PA, a screening for autoimmune thyroid disease is justified, which should first involve the determination 
of TPOAb (further TgAb) in the blood. The assessment of antithyroid antibodies should be recommended primarily to patients with PA, 
who have IFAb and/or APCA, and in particular those with concurrent IFAb and APCA. (Endokrynol Pol 2019; 70 (2): 143–150)
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Introduction 
Pernicious anaemia (PA; Biermer’s disease, Addisonian 
anaemia) is characterised by chronic atrophic gastritis, 
impaired production of intrinsic factor (IF; Castle Fac-
tor) by gastric parietal cells and reduced resorption of 
vitamin B12 from the ileum. IF has transport and protec-
tive functions for vitamin B12. In the clinical picture of 
the disease there are a number of dysfunctions in the 
digestive system (histamine-resistant achlorhydria, 
decreased appetite and body weight, burning and 
tongue pain) and nervous system (muscle weakness, 
atrophy, hearing loss, irritability, depressive disorders, 
impairment of cognitive functions). An increased risk 
of developing stomach cancer in people with PA was 
observed. The haematological clinical symptom is 
megaloblastic anaemia with typical fatigability and 
effort dyspnoea. Pernicious anaemia is an autoim-
mune disease — anti-intrinsic factor antibodies (IFAb) 
(specific) and anti-parietal cell antibodies (APCA) (low 
specificity) are involved in its pathogenesis [1–16]. 
In patients with diagnosed autoimmune disease, 
changes in the functioning of other organs/systems 
often develop with time (or simultaneously). Prob-
ably it is the result of general immune disturbances 
accompanying these diseases as well as cross reac-
tions that show many types of antibodies [13, 16–25]. 
Understanding the pathomechanism of the above 
phenomenon and expanding the diagnosis to detect 
the dysfunction of the other organ even before a clear 
clinical manifestation of the primary disease is justi-
fied, especially because starting the primary disease 
treatment can make this diagnosis more difficult. In 
this context, the coexistence of pathologies of the 
haematopoietic system with an immunological basis 
with other diseases of similar aetiology confirms the 
legitimacy of the implementation of a wider panel of 
examinations at the onset of the initial symptoms of 
one of the diseases mentioned above.
The aim of the study was to determine the fre-
quency of occurrence of antibodies participating in the 
development of endocrine diseases in patients with 
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— pernicious anaemia. There were 85 women and 39 men aged: ≥ 60 
(61.3%), 50–59 (20.2%), 40–49 (12.1%), and 30–39 (6.5%) years old. The 
male/female sex ratio was 0.46. Criteria for inclusion: over 18 years of 
age; diagnosed PA based on at least two of three diagnostic criteria: 
 — reduced serum B12 level (below 200 pg/mL);
 — positive result for one of the following antibodies: IFAb 
and/or APCA;
 — positive a therapeutic test, i.e. precisely defined by laboratory 
parameters, response to a single parenteral administration of 
1000 μg of vitamin B12 in the form of an increase in the number 
of reticulocytes after 5–10 days (reticulocytic break), reduction 
of iron or LDH in the blood by 50% of baseline, regression of 
thrombocytopaenia or/and neutropoenia within two weeks, 
regression of anaemia and hyper-segmentation of granulocyte 
nuclei after 2–4 weeks. 
Exclusion criteria: under 18 years of age; cancer; chronic renal failure 
(eGFR < 30 ml/min/1.73m2); chronic hepatic failure (bilirubin above 
2 mg%); symptomatic circulatory insufficiency; symptomatic respi-
ratory failure; severe neurological diseases and mental disorders. 
The control group (C) comprised 41 people: 30 women and 11 men, 
of comparable age to the study group. Criteria for inclusion: over 
18 years of age; exclusion of autoimmune disease based on the 
interview and available test results; negative antibody result of 
IFAb and APCA; no clinical signs of organ dysfunction; exclusion 
of chronic pharmacotherapy; negative history of autoimmune 
diseases in the family. In both groups (PA, C) blood for testing up 
to 20 ml was collected in the morning, after an overnight fast, from 
the ulnar vein, using a vacuum system. Serum/plasma was stored 
at –75°C until antibody determination.
Methods
IFAb (IgG) and APCA (IgG) were determined by enzyme-linked 
immunosorbent assay (ELISA) using a test kit from by EUROIM-
MUN Medizinische Labordiagnostika AG (Germany). IFAb was 
quantified. The interpretation of test results accepted in the experi-
ment was as follows: < 20 RU/mL — negative result; ≥ 20 RU/mL 
— positive result. APCA rated semi-quantitatively. The interpre-
tation of test results accepted in the experiment was as follows: 
negative result; positive result. 
TPOAb (IgG) was determined by ELISA and quantified. The in-
terpretation of the test results accepted in the experiment were as 
follows: < 100 IU/mL — negative result; ≥ 100 IU/mL — positive 
result. The assays were performed using an ELISA test kit from IBL 
International GmBH, Germany. The upper limit of the standard 
(cut-off) recommended by the manufacturer of the set is 100 IU/mL. 
IBL recommends the following interpretation of the test results: 
< 85 IU/mL — negative result, 85–125 IU/mL — uncertain result, 
> 125 IU/mL — positive result. IBL assessed the level of TPOAb in 
160 healthy blood donors (appropriately divided by age and sex) 
and showed TPOAb values as follows: mean — 55 IU/mL, mean 
+ 2SD — 220 IU/mL, median 35 IU/mL, 95% (percentile) of results 
≤ 110 IU/mL (reference group). The linearity of the ELISA used was 
within the measurement range of 15–2100 IU/mL. The lower limit 
of detection (analytical sensitivity) of the test used was 10 IU/mL. 
This limit was defined as three times the standard deviation of the 
blind test and was the lowest value of the TPOAb measured. The 
test kit is specific for human IgG antibodies against TPO (analytical 
specificity). Evaluated in order to control repeatability, the coeffi-
cient of variation (CV) measurements within the same assay (intra-
assay-variation) and the variation coefficient measurements carried 
out at intervals of time (inter-assay-variation) in different ranges 
of the calibration curve were 3.7–4,1%, and 4.1–7%, respectively. 
TgAb (IgG) was determined by ELISA and quantified. The inter-
pretation of the test results accepted in the experiment was as 
follows: < 100 IU/mL — negative result; ≥ 100 IU/mL — positive 
result. The assays were performed using an ELISA test kit from 
IBL International GmBH, Germany. The cut-off recommended 
by the manufacturer of the set is 100 IU/mL. IBL recommends the 
following interpretation of the test results: < 85 IU/mL — negative 
autoimmune haematopoietic disease (PA), thus docu-
menting the potential suitability of specific diagnostic 
and screening tests.
Characteristics of the antibodies tested
IFAb are specific for PA but are not detected in all 
patients. The diagnostic sensitivity of APCA for PA is 
very high; however, the specificity is limited due to the 
numerous other diseases in which these antibodies are 
present. APCA are detected in almost every case of PA, 
but often also in the course of gastritis without anaemia. 
APCA does not occur in healthy people [3, 4, 8, 9, 13, 
14, 16, 20, 26–29].
High titres of anti-thyroid peroxidase antibodies 
(TPOAb) and/or anti-thyroglobulin antibodies (TgAb) 
are typical for autoimmune thyroid disease (AITD) 
— Hashimoto disease (atrophic or with goitre), and 
Graves’ disease. Their concentration in the blood often 
correlates with the clinical condition. These antibodies 
are responsible for the destruction of thyrocytes. They 
can occur in a low percentage of healthy people, and 
their occurrence in the population increases with 
age. TPOAb and TgAb were found in people without 
clinical biochemical and ultrasonographic symptoms 
of diseases of the thyroid gland are a predictor of their 
development, in particular of hypothyroidism. 
Anti-adrenal antibodies (AdrenalAb) are detected in 
some patients with Addison’s disease, often after many 
years, and their concentration does not correlate with the 
course of the disease. These antibodies are primarily di-
rected against steroid 21-hydroxylase. Addison’s disease 
in 60–80% of cases has an autoimmune basis, which is 
associated with the destruction of the adrenal cortex and 
leads to its failure in the secretion of glyco- and miner-
alocorticoids. These antibodies are rarely determined by 
clinicians, and only their clinical utility is evaluated [25]. 
Anti-pituitary antibodies (PituitaryAb) probably 
arise not only in patients with autoimmune pituitary 
inflammation, but also as a result of necrosis, damage, 
or inflammation such as lymphocytic pituitary inflam-
mation. Their participation in the pathomechanism of 
pituitary insufficiency has not yet been determined. 
These antibodies are extremely rarely determined by 
clinicians, and their clinical utility is also being evalu-
ated [30–33]. 
Material and methods
Patients
The research project was approved by the Bioethical Commission 
of the Medical University of Silesia (Resolution No. KNW/0022/
KB1/84/10). All subjects gave informed consent to participate in the 
study. The study group (PA) was made up of 124 people with a newly 
diagnosed autoimmune disease of the haematopoietic system 
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result, 85–125 IU/mL — uncertain result, > 125 IU/mL — positive 
result. IBL assessed the level of TgAb in 160 healthy blood donors 
(appropriately divided by age and sex) and showed TgAb values: 
mean — 35 IU/mL, mean + 2SD — 110 IU/mL, median 25 IU/mL, 
95% (percentile) of results (reference group). The linearity of the 
ELISA used was within the measurement range of 15–2300 IU/mL. 
The lower detection limit of the assay used was 10 IU/mL. This 
limit was defined as three times the SD of the blind test and was 
the lowest value of the determined TgAb titre. The test kit is specific 
for human IgG antibodies against Tg. Intra-assay-variation and 
inter-assay-variation in different ranges of the standard curve are 
2.7–6.9% and 2.7–7.4%, respectively. 
AdrenalAb was determined by indirect immunofluorescence assay 
(IIFT) and rated qualitatively. The interpretation of test results ac-
cepted in the experiment was as follows: negative result; positive 
result. The assays were performed using the EUROIMMUN Med-
izinische Labordiagnostika AG test kit, Germany, which is intended 
for the in vitro testing of human antibodies against the adrenal 
cortex in serum or plasma. Frozen primate adrenal gland sections 
are incubated with diluted patient samples. In positive cases, spe-
cific antibodies of the IgA, IgG, and IgM class bind to the adrenal 
antigens. During the second incubation step, bound antibodies are 
detected by fluorescein-labelled anti-human antibodies, and this 
reaction is evaluated under a fluorescence microscope. The image 
of fluorescence (positive reaction) arises because AdrenalAb reacts 
with frozen primate adrenal glands, and in the cortical region, the 
cytoplasm of steroid-producing cells exhibits granular or uniform 
fluorescence. 
PituitaryAb was determined by indirect immunofluorescence assay 
(IIFT) and assessed qualitatively. The interpretation of test results 
accepted in the experiment was as follows: negative result; posi-
tive result. The assays were performed using the EUROIMMUN 
Medizinische Labordiagnostika AG test kit, which is intended for 
the in vitro testing of human anti-pituitary (frontal lobe) antibodies 
in serum or plasma. Frozen primate pituitary gland sections are 
incubated with diluted patient samples. In positive cases, specific 
antibodies of the IgA, IgG, and IgM class bind to pituitary antigens. 
During the second incubation step, bound antibodies are detected 
by fluorescein-labelled anti-human antibodies, and this reaction 
is evaluated under a fluorescence microscope. Fluorescence (posi-
tive reaction) is produced because pituitary antibodies react with 
different pituitary structures, and in cells producing hormones of 
the anterior pituitary gland, granular cytoplasmic fluorescence is 
visible (the target antigen for these antibodies may be prolactin-
producing cells). 
The test kits used for the AdrenalAb and PituitaryAb assays do not 
show cross-reactivity and interference with haemolytic, lipaemic, 
and hyperbilirubinaemia sera. The results for all samples of 10 dif-
ferent series evaluated for repeatability control differed by no more 
than ± 1 degree of fluorescence intensity (thus the reproducibility 
of the test was confirmed). The intensity of specific fluorescence in 
the form of a numerical value is called the fluorescence intensity 
level. These values range from “0” (no specific fluorescence) to “5” 
(extremely strong fluorescence). Inter-serial repeatability also did 
not differ by more than ± 1 degree of fluorescence intensity. With 
the same result, the reproducibility of the test was confirmed. The 
sensitivity and specificity of the IIFT test used is 100%, and these 
values were determined from the tests of samples previously clas-
sified by the reference centres.
Vitamin B12, iron, ferritin, folic acid; peripheral blood count with 
smear and platelets by manual method, INR, APTT, PT, fibrinogen, 
D-dimers; proteinogram, total protein; basic biochemical tests (cre-
atinine, glucose, bilirubin, Alat, electrolytes, lipidogram, uric acid, 
CRP); and TSH, fT4, and fT3 were determined with routine kits using 
biochemical analysers in the course of haematological diagnostics. 
Statistical methods and tools 
In the statistical elaboration, variables were available in qualita-
tive (nominal) form (IFAb, APCA, TPOAb, TgAb, PituitaryAb, 
AdrenalAb) and three parameters on the quantitative scale (IFAb, 
TPOAb, TgAb). Relations for which p < 0.05 were considered as 
important. To assess the relationship between the nominal values 
of antibodies, the Pearson's Chi-squared independence test was 
used. A hierarchy of risk of antibody development in the study 
group was developed. Risk models for the emergence of antithyroid 
antibodies in the study group were performed. For these variables, 
logarithmic-normal distributions were used that describe the dis-
tribution of these antibodies. The study used a multidimensional 
MCA correspondence model for the occurrence of certain groups 
of antibodies in the study group. Thanks to this analysis, groups 
of clusters of certain measured parameters, i.e. age, sex, antibodies, 
and diseases caused by them, could be selected. In the last part of 
the analysis for quantitative variables, Pearson’s correlations were 
calculated.
Results
The presence of at least one of the two antithyroid 
antibodies involved in the pathogenesis of AITD af-
fects more than 40% of patients with PA. TPOAb is 
found in patients with PA more often than TgAb, and 
simultaneous occurrence of TPOAb and TgAb in the 
blood of these patients occurs in every fifth patient. 
AdrenalAb and PituitaryAb in PA patients occur spo-
radically. In those considered healthy (control group), 
approximately 12% had at least one of two analysed 
antithyroid antibodies, and the percentage of both 
antibodies was 2.4%. TgAb was twice as likely to be 
present in this group than TPOAb. AdrenalAb and Pi-
tuitaryAb are not found in healthy persons (Tab. I, II). 
Analysis of the coexistence of these antibodies showed 
that patients with PA lack the basis for recognising 
APS variants with respect to the analysed antibodies 
(Tab.  III) as summarised in the probabilistic assess-
ment of the odds [0–100%] and the risk of appearance 
of antibodies to endocrine glands in patients with PA. 
The risk of the presence of antibodies against endocrine 
glands in patients with PA can be classified in the fol-
lowing order: TPOAb and/or TgAb — 41.1%, TPOAb 
— 36.3%, TgAb — 25.0%, TPOAb and TgAb — 20.2%, 
AdrenalAb — 1.6%, PituitaryAb — 0.8% (Tab. IV). For 
the most common antibodies, a model of risk/chance 
of their occurrence in patients with PA was performed. 
These data (Fig. 1, 2) are consistent with the calculations 
presented earlier (Tab. I, IV). In order to verify the thesis 
whether in patients with PA there is correlation in the 
simultaneous occurrence of antibodies involved in the 
development of autoimmune endocrine diseases (AITD, 
APS) with antibodies involved in the pathogenesis of 
PA, the c2 independence test was used. TPOAb and/or 
TgAb (mainly TPOAb) are more frequently present in 
patients with PA, who have IFAb and/or APCA. This 
correlation is most evident in patients with concurrent 
IFAb and APCA (Tab. V). This analysis was extended 
by multidimensional analysis of MCA correspondence 
of the occurrence of antibody groups in patients with 
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PA, which allowed us to create a statistically significant 
(c2 = 4584.51; p < 0.01) model (distribution of factors 
and their clusters on the Burt matrix) based on which 
it has been shown that the simultaneous presence of 
antibodies “IFAb and/or APCA” with antibodies “TPOAb 
and/or TgAb” is most likely in women over 45 years of 
age (data not included in the table/figure).
For the quantified antibodies [IU/mL], descriptive 
statistics were calculated. TPOAb in the PA group: 
mean 199.5 ± SD 326.94; min. 1.53; max. 1548.4; median 
26.85. TPOAb in group C: mean 30.6 ± SD 74.71; min. 
0; max. 460,51; median 11.82. TgAb in the PA group: 
mean 442.11 ± SD 1281.37; min. 3.3; max. 6781.34; 
median 34.72. TgAb in group C: mean 60.63 ± SD 
131.12; min. 4.7; max. 607.92; median 15.89 (data not 
included in the table). In the last stage of the analysis, 
Pearson’s correlations were calculated for quantitative 
determinations in the blood. In the PA group, if the 
concentration of IFAb in the blood increases, then 
the concentration of TgAb will increase slightly. In 
addition, a moderately increased amount of TPOAb 
is accompanied by an increase in the amount of TgAb 
(Tab. VI). In group C, a moderately strong increase in 
TPOAb was accompanied by an increase in the amount 
of TgAb (R = 0.639, p < 0.01) (data not included in 
the table).
Table I. Prevalence of antibodies involved in the development of autoimmune thyroid disease (AITD) i.e. anti-thyroid peroxidase 
(TPOAb) and anti-thyroglobulin (TgAb) antibodies in pernicious anaemia patients (PA) and in control (C) groups
Antibodies Response
Group c2 test
Pernicious anaemia (PA)  
% (n)
Control (C) 
% (n) c
2 df p
TPOAb
Negative result 63.70% (79) 95.10% (39)
14.925 1 0.000
Positive result 36.30% (45) 4.90% (2)
TgAb
Negative result 75.00% (93) 90.20% (37)
4.284 1 0.038
Positive result 25.00% (31) 9.80% (4)
TPOAb and/or TgAb
Negative result 58.90% (73) 87.80% (36)
11.505 1 0.001
Positive result 41.10% (51) 12.20% (5)
TPOAb and TgAb
Negative result 79.80% (99) 97.60% (40)
7.29 1 0.007
Positive result 20.20% (25) 2.40% (1)
n — number of patients/controls
Table II. Prevalence of anti-adrenal gland (AdrenalAb) and anti-pituitary gland (PituitaryAb) antibodies in pernicious 
anaemia patients (PA) and in control (C) groups
Antibodies Response
Group c2 test
Pernicious anaemia (PA)  
% (n)
Control (C) 
% (n) c
2 df p
AdrenalAb Positive result 1.60% (2) 0% (0) 0.669 1 0.413
PituitaryAb Positive result 0.80% (1) 0% (0) 0.333 1 0.564
n — number of patients/controls
Table III. Coexistence of antibodies involved in the development of possible variants of autoimmune polyendocrine syndrome 
(APS) in pernicious anaemia patients (PA) and in control (C) groups
Coexistence of antibodies Response 
Group c2 test
Pernicious anaemia (PA)  
% (n)
Control (C) 
% (n)
c2 df p
TPOAb and TgAb + AdrenalAb Positive result 0.80% (1) 0% (0) 0.333 1 0.564
TPOAb or TgAb + PituitaryAb Positive result 0% (0) 0% (0)
AdrenalAb + PituitaryAb Positive result 0% (0) 0% (0)
n — number of patients/controls
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Discussion
Among 126 Chinese PA patients, 44% had TPOAb/TgAb 
and 13.5% AITD. TPOAb/TgAb occurred in 33% (16 of 
49) of male and 52% (40 of 77) of female patients. The 
TPOAb/TgAb did not affect the clinical course of PA 
but was associated with an enhanced risk of develop-
ing AITD and vitiligo. Overall, AITD (before and after 
the appearance of PA) occurred in 23% (13 of 56) and 
5.7% (4 of 70) of the patients with and without APCA 
(IFAb, was not determined) [34]. In turn, in a recently 
published retrospective observation of 188 patients with 
PA, non-haematological diseases with autoimmune 
aetiology were sought. Diagnosis of AITD was based 
on clinical examination and the presence of TPOAb 
and/or TgAb. Diagnosis of Addison’s disease was based 
on clinical data, hormonal status, and the presence of 
anti-adrenal antibodies. In a newly formed group of 
74 (male 13, female 61, male/female sex ratio 0.2; age 
range 25–98 years) patients with PA and at least one 
other autoimmune disease the following was shown: 
Hashimoto’s disease in 45 people (60.8 % in 36 women 
and nine men), Addison’s in five (6.8%) and Graves’ 
in 12 people (16.6%) [25]. In our study, in the group 
of 124 people with PA, TPOAb and/or TgAb occur in 
41.1% and AdrenalAb in 1.6%. The results from the two 
above-mentioned articles seem to be consistent with 
those obtained by us. In our work, the risk of having 
antithyroid antibodies in patients with PA is addition-
ally attributed to their specific types. We also show 
that TPOAb and/or TgAb (mainly TPOAb) are more 
frequently present in patients with PA who have IFAb 
and/or APCA, and this relationship is most evident in 
patients with associated occurrence both of IFAb and 
APCA. We also point out that in patients with PA, the 
simultaneous presence of antibodies IFAb and/or APCA 
with TPOAb and/or TgAb antibodies is most likely in 
women over 45 years of age. In view of the fact that PA 
usually affects adults over 60 years of age, but about 
50% of patients are < 60 years old [11], we assessed the 
levels of antithyroid antibodies in relation to age. So far, 
the association between AITD and PA among people 
aged 65 years or older has been confirmed, as well as 
a progressive increase in the incidence of these diseases 
Table IV. Risk of the presence of endocrine gland antibodies 
in pernicious anaemia patients
Risk of the presence of endocrine gland antibodies  
in pernicious anaemia patients 
TPOAb and/or TgAb 41.1%
TPOAb 36.3%
TgAb 25.0%
TPOAb and TgAb 20.2%
AdrenalAb 1.6%
PituitaryAb 0.8%
TPOAb and/or TgAb + AdrenalAb 0.8%
TPOAb + AdrenalAb 0.8%
TgAb + AdrenalAb 0.8%
TPOAb and TgAb + AdrenalAb 0.8%
TPOAb or TgAb + PituitaryAb ~0.0%
AdrenalAb + PituitaryAb ~0.0%
TPOAb — anti-thyroid peroxidase antibody; TgAb — anti-thyroglobulin antibody; 
AdrenalAb — anti-adrenal gland antibody; PituitaryAb — anti-pituitary gland 
antibody
Figure 2. The risk/chance of a positive TgAb result ≥ 100 IU/mL 
in patients with pernicious anaemia (PA). The risk function 
for TgAb of the occurrence of x value on the above-mentioned 
scale variable is expressed by the formula *TgAb [IU/mL] 
= 128*iLognorm (x; 4.0654; 1.7032)
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Figure 1. The risk/chance of TPOAb positive result ≥ 100 IU/mL 
in patients with pernicious anaemia (PA). The risk function 
for TPOAb of the occurrence of x value on the above-mentioned 
scale variable is expressed by the formula *TPOAb [IU/mL] 
= 126*iLognorm (x; 3.7854; 1.9426)
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[35]. In almost half of the PA patients we examined, we 
found a clear increase in the amount of at least one of 
the two antibodies responsible for the development 
of AITD, which is sufficient to recognise the increased 
risk of Hashimoto’s disease, and in combination with 
hormonal and ultrasound assessment determines the 
diagnosis of this most common thyroid disease. We 
found both TPOAb and TgAb in every fifth patient with 
PA, which suggests an even deeper autoimmune alert. In 
our study, in patients with PA, TPOAb is more frequent 
than TgAb. There is a widespread opinion that among 
these two antibodies for the diagnosis of AITD, TPOAb 
is more specific. Considering this, screening for AITD 
should start with the TPOAb determination. We also 
Table V. Coexistence of antibodies involved in the development of autoimmune endocrine disease (AITD, APS) with antibodies 
involved in the pathogenesis of pernicious anaemia in the pernicious anaemia patient group (PA)
Antibodies Result 
IFAb APCA IFAb and/or APCA IFAb and APCA
Negative Positive Negative Positive Negative Positive Negative Positive
% (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n)
TPOAb
Negative 72.10% (62)
44.70% 
(17)
74.60% 
(50)
50.90% 
(29)
79.20% 
(38)
53.90% 
(41)
70.50% 
(74)
26.30%  
(5)
Positive 27.90% (24)
55.30% 
(21)
25.40% 
(17)
49.10% 
(28)
20.80% 
(10)
46.10% 
(35)
29.50% 
(31)
73.70% 
(14)
TPOAb  
and/or TgAb
Negative 65.10% (56)
44.70% 
(17)
67.20% 
(45)
49.10% 
(28)
68.80% 
(33)
52.60% 
(40)
64.80% 
(68)
26.30%  
(5)
Positive 34.90% (30)
55.30% 
(21)
32.80% 
(22)
50.90% 
(29)
31.30% 
(15)
47.40% 
(36)
35.20% 
(37)
73.70% 
(14)
Antibodies IFAb APCA IFAb and/or APCA IFAb and APCA
TPOAb
c2 8531 7.514 8.093 13.57
df 1 1 1 1
p 0.003 0.006 0.004 0
TPOAb and/or TgAb
c2 4.521 4.14 9.821
df 1 1 NS 1
p 0.033 0.042 0.002
TgAb p NS NS NS NS
AdrenalAb p NS NS NS NS
PituitaryAb p NS NS NS NS
TPOAb and TgAb p NS NS NS NS
TPOAb and/or TgAb + AdrenalAb p NS NS NS NS
TPOAb + AdrenalAb p NS NS NS NS
TgAb + AdrenalAb p NS NS NS NS
TPOAb and TgAb + AdrenalAb p NS NS NS NS
TPOAb and/or TgAb + PituitaryAb . . . . .
TPOAb + PituitaryAb . . . . .
TgAb + PituitaryAb . . . . .
TPOAb and TgAb + PituitaryAb . . . . .
AdrenalAb and PituitaryAb . . . . .
TPOAb — anti-thyroid peroxidase antibody; TgAb — anti-thyroglobulin antibody; AdrenalAb — anti-adrenal gland antibody; PituitaryAb — anti-pituitary 
gland antibody; IFAb — anti-intrinsic factor antibody; APCA — anti-parietal cell antibody; NS — no significance; n — number of patients
Table VI. Pearson correlations for the group with pernicious 
anaemia (PA)
PA group Age IFAb TPOAb TgAb
Age
R 1 0.054 –0.091 –0.065
p 0.550 0.316 0.473
IFAb
[RU/mL]
R 0.054 1 0.136 0.203
p 0.550 0.133 0.024
TPOAb 
[IU/mL]
R –0.091 0.136 1 0.490
p 0.316 0.133 0.01
TgAb
[IU/mL]
R –0.065 0.203 0.490 1
p 0.473 0.024 < 0.01
R — correlation coefficient
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describe the incidence of AdrenalAb in patients with 
PA. We were the first to investigate the incidence of Pitu-
itaryAb, not only in patients with PA but also in patients 
with autoimmune haematological disease in general.
Although the results of previously published re-
search related to the clinical issue described here are 
varied, they sometimes depend on the studied popula-
tion, but still prove the existence of an autoimmune alert 
in patients with PA. For example, in the Korean popula-
tion, Hashimoto’s thyroiditis was found in 6.1% (6 out 
of 97) of PA patients, vitiligo in 3%, and Graves’ disease 
in 4.1%. Type 1 diabetes mellitus, Addison’s disease, and 
ankylosing spondylitis were found in one patient each. 
Two per cent of patients already had stomach cancer 
at the time of diagnosis of PA. In total, AITD was pres-
ent in 10.2% of this study population, which is much 
lower than the 24% to 27% in Western populations [6]. 
At present, it is difficult to explain such a distinct dif-
ference. Another newly published work shows, that 
40% of patients with autoimmune gastritis also present 
Hashimoto’s thyroiditis [23]. The issue discussed here 
was also analysed in the opposite way - the incidence 
of PA in patients with non-haematopoietic autoimmune 
disease was examined. PA is sometimes preceded by 
AITD [21] by several years. A prevalence of IFAb at 
3.5%, being higher in patients with AITD than in those 
with non-autoimmune thyroid dysfunction, was found 
[36]. In 12% of patients with Addison’s disease, IFAb is 
found [37]. 23.5% patients with AITD were diagnosed 
with APCA [38]. APCA positivity was significantly 
more prevalent in Hashimoto than in non-Hashimoto 
thyroiditis patients (12.9 vs. 1.6 %, p = 0.017) [39]. PA 
was found in 18.6% of the patients with AITD, and the 
45% of PA presented with AITD, mainly in women 
(RR = 6.0). The average time in diagnosing the second 
disease was about eight years. When there was a third 
autoimmune disease the likelihood of AITD and PA 
increased fourfold. Patients with AITD and taking drugs 
that affected the absorption of vitamin B12 had double 
the probability of developing a PA compared with those 
who were not taking medications [35]. The occurrence 
of anti-thyroid antibodies in patients with PA has also 
been described much earlier at the level of 33% [17], 
which is consistent with the clinical observation of 
the coexistence of diseases with autoimmune aetiol-
ogy in clinical medicine [13, 16, 18–20]. Susceptibility 
to PA appears to be genetically determined, although 
the mode of inheritance remains unknown. Similarly, 
there is evidence for the role of genetic factors binding 
PA with other autoimmune diseases [4, 19–22]. The 
phenomenon of the coexistence of autoimmune dis-
eases of the endocrine glands with gastroenterological 
and rheumatic diseases is referred to as autoimmune 
polyendocrine syndrome (APS). APS has a number of 
types and subtypes. The coexistence of PA and AITD 
forms APS type IIIb alongside such autoimmune dis-
eases as diabetes, alopecia, vitiligo, and chronic atrophic 
gastritis. In APS IIIb, Hashimoto thyroiditis represents 
the pivotal disorder. Progress has been made in the 
diagnosis of autoimmune diseases in recent years, 
also in terms of sensitivity and specificity of antibody 
determinations, which was an additional justification 
for conducting this analysis.
Conclusions
In patients with pernicious anaemia it is justified to carry 
out screening evaluation towards autoimmune thyroid 
diseases, which in the first place should be based on 
a determination of the concentration of TPOAb (next 
TgAb) in the blood. The assessment of antithyroid an-
tibodies should be recommended primarily to patients 
with pernicious anaemia, who have IFAb and/or APCA 
and in particular those with concurrent IFAb and APCA. 
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